Vol. 37 No. 2 (2020)

Click for printable Cover and Index

Published: 08-07-2020

  • Sarcoidosis Vasculitis and Diffuse Lung Disease: alive and still growing

    Robert P. Baughman, Antonella Caminati, Claudia Ravaglia, Luca Richeldi, Paola Rottoli, Sara Tomassetti, Carlo Vancheri
    86
    DOI: https://doi.org/10.36141/svdld.v37i2.10080

  • Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy

    Huzaefah Syed, Christian Ascoli, Catharina Linssen, Christen Vagts, Thomas Iden, Aamer Syed, Jordana Kron, Kelly Polly, David Perkins, Patricia Finn, Richard Novak, Marjolein Drent, Robert Baughman, Nadera Sweiss
    87-98
    DOI: https://doi.org/10.36141/svdld.v37i2.9599

  • The right upper lobe bronchus angle: A tool for differentiating fibrotic and non-fibrotic sarcoidosis

    Mary Salvatore, Danielle Toussie, Nadiya Pavlishyn, David Yankelevitz, Timothy O'Connor, Claudia Henschke, Maria Padilla
    99-103
    DOI: https://doi.org/10.36141/svdld.v37i2.8965

  • Sarcoidosis and increased risk of comorbidities and mortality in Sweden Sarcoidosis - Comorbidities and Mortality

    Johanna Larsson, Pål Graff, Ing-Liss Bryngelsson, Per Vihlborg
    104-135
    DOI: https://doi.org/10.36141/svdld.v37i2.9142

  • Treatment of Primary Sjögren’s Syndrome-Related Interstitial Lung Disease: a Retrospective Cohort Study

    Barkha Amlani, Ghada Elsayed, Umang Barvalia, Jeffrey P Kanne, Keith C Meyer, Nathan Sandbo, Zhanhai Li, Sara S McCoy
    136-147
    DOI: https://doi.org/10.36141/svdld.v37i2.8461

  • A real-world study of the tolerability and dosing of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis Pirfenidone dose and survival in IPF

    Sahajal Dhooria, Ritesh Agarwal, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Valliappan Muthu, Mandeep Garg, Amanjit Bal, Ashutosh Nath Aggarwal, Digambar Behera
    148-157
    DOI: https://doi.org/10.36141/svdld.v37i2.8718

  • Predictors of cough-specific and generic quality of life in sarcoidosis patients

    Branislav S. Gvozdenovic, Violeta Mihailovic-Vucinic, Mira Vukovic, Mihailo Stjepanovic, Ivana Buha, Strahinja V. Mihailovic, Nikola B. Maric
    158-168
    DOI: https://doi.org/10.36141/svdld.v37i2.9234

  • Obstructive sleep apnea in sarcoidosis and impact of CPAP treatment on fatigue

    Pier-Valerio Mari, Giuliana Pasciuto, Matteo Siciliano, Jacopo Simonetti, Federico Ballacci, Francesco Macagno, Bruno Iovene, Filippo Martone, Giuseppe Maria Corbo, Luca Richeldi
    169-178
    DOI: https://doi.org/10.36141/svdld.v37i2.9169

  • A unique case of ovarian manifestation of systemic vasculitis that mimics ovarian cancer.

    Ada Bielejewska, Arkadiusz Bociek, Martyna Bociek, Andrzej Jaroszyński
    179-183
    DOI: https://doi.org/10.36141/svdld.v37i2.8181

  • Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertensio

    Eric Abston, Matthew Moll, Stephanie Hon, Praveen Govender, Jeffrey Berman, Harrison Farber
    184-191
    DOI: https://doi.org/10.36141/svdld.v37i2.9150

  • The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study

    Monique Wapenaar, Elisabeth Bendstrup, Maria Molina-Molina, Maarten K.N. Stessel, Jasmina Huremovic, Eric W. Bakker, Isabella Kardys, Joachim G.J.V. Aerts, Marlies S. Wijsenbeek
    192-202
    DOI: https://doi.org/10.36141/svdld.v37i2.9433

  • Associations between interleukin 18 gene polymorphisms and susceptibility to vasculitis: A meta-analysis IL18 polymorphisms in vasculitis

    Jae Hyun Jung, Han Saem Jeong, Sung Jae Choi, Gwan Gyu Song, Jong-Ho Kim, Tae Hyub Lee, Youngjin Han
    203-211
    DOI: https://doi.org/10.36141/svdld.v37i2.9399

  • Role of alveolar collapse in idiopathic pleuroparenchymal fibroelastosis

    Yoshiaki Kinoshita, Hiroshi Ishii, Hisako Kushima, Masaki Fujita, Kazuki Nabeshima, Kentaro Watanabe
    212-217
    DOI: https://doi.org/10.36141/svdld.v37i2.9981

  • Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study

    James Eaden, Christopher M. Barber, Stephen Renshaw, Nazia Chaudhuri, Stephen Bianchi
    218-224
    DOI: https://doi.org/10.36141/svdld.v37i2.8587

  • Non-tuberculous, adenosine deaminase-positive lymphocytic pleural effusion: Consider immunoglobulin G4-related disease

    Ori Wand, Ben Fox, Osnat Shtraichman, Osnat Moreh-Rahav, Moti Kramer
    225-230
    DOI: https://doi.org/10.36141/svdld.v37i2.9098

  • Rapidly non-IPF progressive fibrosing interstitial lung disease: a phenotype with an IPF-like behavior

    Ngu Khine, Dalia Mudawi, Pilar Rivera-Ortega, Colm Leonard, Nazia Chaudhuri, George A. Margaritopoulos
    231-233
    DOI: https://doi.org/10.36141/svdld.v37i2.9276

  • Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy

    Eric Abston, Stephanie Hon, Romy Lawrence, Jeffrey Berman, Praveen Govender, Harrison W. Farber
    234-238
    DOI: https://doi.org/10.36141/svdld.v37i2.9343

  • Pulmonary arterial hypertension secondary to Takayasu’s Arteritis: management using a combined medical and interventional approach

    Matthew Nitzberg, Raj Parikh, Praveen Govender, Harrison W Farber
    239-241
    DOI: https://doi.org/10.36141/svdld.v37i2.8987

  • Subcutaneous sarcoidosis: a report of 13 cases and its association with extracutaneous sarcoidosis

    Toshiyuki Yamamoto
    242-245
    DOI: https://doi.org/10.36141/svdld.v37i2.9199